Key result
Baseline cardiac autonomic neuropathy was strongly associated with early GFR loss (OR 4.09; 95% CI 1.65-10.12; P=0.002) in patients with type 1 diabetes.
Why the study?
Does baseline cardiac autonomic neuropathy predict early progressive renal decline in patients with type 1 diabetes?
Cohort (n=370)
Does baseline cardiac autonomic neuropathy predict early progressive renal decline in patients with type 1 diabetes?
Odds Ratio: 4.09 (95% CI 1.65–10.12)
Absolute Event Rate: 32% vs 10%
p-value: p=0.002
Cardiac autonomic neuropathy is a strong independent predictor of long-term risk for early progressive renal decline in patients with type 1 diabetes.
No takes yet. Share an insight, caveat, or question.
Cardiac autonomic neuropathy may warrant closer renal monitoring in type 1 diabetes; leaves open whether screening improves outcomes.
Orlov et al. (2015) conducted a cohort in Type 1 diabetes (n=370). Cardiac autonomic neuropathy vs. No baseline cardiac autonomic neuropathy was evaluated on Early GFR loss (slope of eGFR estimated by cystatin C <-3.3%/year) (OR 4.09, 95% CI 1.65-10.12, p=0.002). Baseline cardiac autonomic neuropathy was strongly associated with early GFR loss (OR 4.09; 95% CI 1.65-10.12; P=0.002) in patients with type 1 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: